PepsiCo, Starbucks and Cigna reportedly cut employee weight-loss drug coverage

A report says PepsiCo, Starbucks and Cigna have cut employee insurance coverage for GLP-1 drugs used for weight loss, a class of medicines that can help reduce appetite. The supplied summary does not specify how many employees are affected, the exact scope of the cuts or their effective dates.^[1]

Some eligible patients aged 65 or older may obtain coverage through Medicare, the US federal health insurance program primarily for older people. The report says Zepbound for sleep apnea or Wegovy for heart risk may qualify, with access depending on the patient's diagnosis and coverage arrangements.^[1]

When employer plans reduce weight-loss drug coverage, patients may have to pay more themselves. Some could delay starting treatment or stop taking it, weakening manufacturers' prescription volumes, while employers could reduce their spending on these medicines. The report provides too little detail to estimate lost sales or cost savings.^[1]

For patients who meet the diagnosis and coverage requirements, Medicare may continue to share treatment costs and support some demand. How many patients drugmakers retain will therefore depend partly on access to alternative coverage.^[1]

Impact

What to watch next

• December 7 is the Medicare enrollment deadline cited in the report: whether eligible patients can select plans covering their diagnosis and medicine will affect treatment continuity.^[1]